BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

TAK upcoming catalysts

Takeda: 7 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 12 readout(s) and 3 FDA event(s). Subscribe to TAK (.ics).

Drugs: TAK-360, Maribavir, Zasocitinib, TAK-279, TAK-788, TAK-861, Teduglutide, Pemetrexed, Cisplatin, Carboplatin, Deucravacitinib, Pembrolizumab, Platinum

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2Takeda TAKNCT06812078 A Study of TAK-360 in Adults With Idiopathic HypersomniaIdiopathic Hypersomniarecruiting96
2026-11-30 est.P2Takeda TAKNCT06952699 A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Narcolepsy Type 2recruiting88
2026-12-17 est.P3Takeda TAKNCT07363720 A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyNarcolepsy Type 1 (NT1); Narcolepsy With Cataplexyactive not recruiting98
2027-01-18 est.P3Takeda TAKNCT05319353 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in CCytomegalovirus (CMV)recruiting80
2027-02-05 est.P2Takeda TAKNCT07244263 A Study of Zasocitinib in Adults With Hidradenitis SuppurativaHidradenitis Suppurativaactive not recruiting91
2027-02-10 est.P3Takeda TAKNCT06973304 A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeShort Bowel Syndromeactive not recruiting13
2027-02-17 est.P2Takeda TAKNCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseCrohn's Diseaserecruiting268

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-08-28FDA approvalapprovedTAKEDA PHARMS AM TAKMIMRYLOApproved 2026-08-28: MIMRYLO (NDA220605 ORIG1)
2026-08-05FDA approvalapprovedTAKEDA PHARMS USA TAKORZEYFULApproved 2026-08-05: ORZEYFUL (NDA220860 ORIG1)
2025-11-21FDA approvalapprovedTAKEDA PHARMS USA TAKLIVTENCITYApproved 2025-11-21: LIVTENCITY (NDA215596 SUPPL7)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-29P1/P2Takeda TAKNCT02716116 A Study of TAK-788 in Adults With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lungcompleted324
2026-09-22P3Takeda TAKNCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)completed354
2026-07-22P3Takeda TAKNCT06439342 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) InfectionsCytomegalovirus (CMV)completed20
2026-07-21P2Takeda TAKNCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldGastroesophageal Reflux Disease (GERD)completed71
2026-07-14P2Takeda TAKNCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting213
2026-06-29P3Takeda TAKNCT07047521 A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsDengue Feveractive not recruiting496
2026-04-22P3Takeda TAKNCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisPlaque Psoriasiscompleted606
2026-04-16P2Takeda TAKNCT05714969 A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)Thrombotic Thrombocytopenic Purpura (TTP)completed29
2026-04-13P2Takeda TAKNCT02615184 A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years OldErosive Esophagitisterminated24
2026-03-30P1/P2Takeda TAKNCT04420884 A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsSolid Neoplasmscompleted248
2026-01-20P2/P3Takeda TAKNCT05755035 A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency DiseasesPrimary Immunodeficiency Diseases (PID)completed65
2025-12-09P2Takeda TAKNCT04530123 Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-FreCeliac Diseasecompleted102

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.